Drug Detail

Information about BKM120 + GSK1120212

Generic Name
IND	BKM120 + GSK1120212
Brand Name (US)
Manufacturer	Novartis + GlaxoSmithKline
Drug Type	Kinase inhibitor
Delivery	Oral + Oral
Approval Status
Indications	soild tumors + melanoma
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths
Drug Category	PI3K inhibitor + MEK inhibitor

Links
Trials of this drug
	A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Trial results